Clinical Practice Recommendations for the Use of Next-generation Sequencing in Patients with Solid Cancer: a Joint Report from KSMO and KSP

Overview

Journal J Pathol Transl Med

Specialty Biomedical Engineering

Date 2024 Jul 19

PMID 39026440

Authors

Miso Kim

Hyo Sup Shim

Sheehyun Kim

In Hee Lee

Jihun Kim

Shinkyo Yoon

Hyung-Don Kim

Inkeun Park

Jae Ho Jeong

Changhoon Yoo

Jaekyung Cheon

In-Ho Kim

Jieun Lee

Sook Hee Hong

Sehhoon Park

Hyun Ae Jung

Jin Won Kim

Han Jo Kim

Yongjun Cha

Sun Min Lim

Han Sang Kim

Choong-Kun Lee

Jee Hung Kim

Sang Hoon Chun

Jina Yun

So Yeon Park

Hye Seung Lee

Yong Mee Cho

Soo Jeong Nam

Kiyong Na

Sun Och Yoon

Ahwon Lee

Kee-Taek Jang

Hongseok Yun

Sungyoung Lee

Jee Hyun Kim

Wan-Seop Kim

Affiliations

Soon will be listed here.

Abstract

In recent years, next-generation sequencing (NGS)-based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Kingston B, Cutts R, Bye H, Beaney M, Walsh-Crestani G, Hrebien S . Genomic profile of advanced breast cancer in circulating tumour DNA. Nat Commun. 2021; 12(1):2423. PMC: 8065112. DOI: 10.1038/s41467-021-22605-2. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Heinrich M, Rankin C, Blanke C, Demetri G, Borden E, Ryan C . Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. 2017; 3(7):944-952. PMC: 5727908. DOI: 10.1001/jamaoncol.2016.6728. View

Westover D, Zugazagoitia J, Cho B, Lovly C, Paz-Ares L . Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018; 29(suppl_1):i10-i19. PMC: 6454547. DOI: 10.1093/annonc/mdx703. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

Abou-Alfa G, Macarulla T, Javle M, Kelley R, Lubner S, Adeva J . Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(6):796-807. PMC: 7523268. DOI: 10.1016/S1470-2045(20)30157-1. View

10.

Luchini C, Bibeau F, Ligtenberg M, Singh N, Nottegar A, Bosse T . ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019; 30(8):1232-1243. DOI: 10.1093/annonc/mdz116. View

11.

Lotan T, Tomlins S, Bismar T, van der Kwast T, Grignon D, Egevad L . Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. Am J Surg Pathol. 2020; 44(7):e15-e29. DOI: 10.1097/PAS.0000000000001450. View

12.

Lord C, Ashworth A . The DNA damage response and cancer therapy. Nature. 2012; 481(7381):287-94. DOI: 10.1038/nature10760. View

13.

Watkins J, Irshad S, Grigoriadis A, Tutt A . Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014; 16(3):211. PMC: 4053155. DOI: 10.1186/bcr3670. View

14.

Fumet J, Truntzer C, Yarchoan M, Ghiringhelli F . Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. Eur J Cancer. 2020; 131:40-50. PMC: 9473693. DOI: 10.1016/j.ejca.2020.02.038. View

15.

Subbiah V, Kreitman R, Wainberg Z, Cho J, Schellens J, Soria J . Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022; 33(4):406-415. PMC: 9338780. DOI: 10.1016/j.annonc.2021.12.014. View

16.

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 383(24):2345-2357. DOI: 10.1056/NEJMoa2022485. View

17.

Van den Heerik A, Horeweg N, Nout R, Lutgens L, van der Steen-Banasik E, Westerveld G . PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020; 30(12):2002-2007. PMC: 7788476. DOI: 10.1136/ijgc-2020-001929. View

18.

Iannantuono G, Riondino S, Sganga S, Roselli M, Torino F . Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review. Int J Mol Sci. 2022; 23(7). PMC: 8999731. DOI: 10.3390/ijms23073995. View

19.

Toh M, Ngeow J . Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications. Oncologist. 2021; 26(9):e1526-e1537. PMC: 8417864. DOI: 10.1002/onco.13829. View

20.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View